RE:RE:RE:nr-- this makes it now clear the voucher $ is very near... Hahaha, wouldn't buy a single share here. You have an incredibly compelling argument on why they didn't estimate any date! I mean, they could use Q2 or Q3 or Q4 to give some specificity, right? You must be right. LOL LOL
So, we'll probably see some huge revenues piling in for Liminal on those contract manufacturing jobs, huh? I bet this alone will triple the share price?
What will they work on with $70M PRV money when it does show up? Preclinical molecules? One year of cash maybe as we all know that they are burning $8M a month right now. Still can't reel their huge salaries in. Pritchard must be incredible with his accounting expertise!! Even better than Galbraith, the guy you posted 3 times a day until he ran away very, very fast.
tommyjones1 wrote:
Yes it does Mr PLitheone. Kedrion will want control of their investment and get things rolling now, not in 2022. lmnl said 2021 at large because the dont have the date it will be announced. Were you the one buying after hours?
stockbuphoon wrote:
This press release doesn't mean sale of PRV is any closer, you dumba$$. Management guidance was sometime in 2021 and they pay plasma division expenses until they sell it
tommyjones1 wrote:
LAVAL, QC and CAMBRIDGE, England, July 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a clinical-stage biopharmaceutical company, announced today that it has closed on the previously announced divestment of its plasma-derived therapeutics manufacturing subsidiary to Kedrion S.p.A. ("Kedrion") (the "First Closing"). The manufacturing facility is operated through Liminal BioSciences' subsidiary, Prometic Bioproduction Inc. ("PBP").
The consideration received by Liminal for PBP was USD 5 million, which was received upon closing, subject to adjustments. Liminal will also be entitled to receive 70% of the net proceeds from a sale of the Rare Pediatric Disease Priority Review Voucher ("PRV") by its subsidiary, Prometic Biotherapeutics Inc. ("PBT"), which would be payable to Liminal prior to closing the divestment of its remaining plasma-derived therapeutics business operated through PBT (the "Second Closing"). PBT is the holder of the biological license application ("BLA") for Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). The Second Closing is subject to the fulfilment of certain conditions precedent, including the sale of the PRV by PBT.